Faricimab is a recombinant humanized bispecific monoclonal antibody designed to target and inhibit two important pathways involved in retinal vascular disease: vascular endothelial growth factor A (VEGF-A) and angiopoietin-2 (Ang-2). It is produced using recombinant DNA technology in Chinese hamster ovary (CHO) cells and belongs to the biological pharmaceutical/API category.
Faricimab is an engineered IgG1 bispecific antibody that simultaneously binds VEGF-A and Ang-2. By inhibiting these two signaling pathways, Faricimab helps reduce abnormal vascular permeability and pathological angiogenesis associated with retinal diseases.
Faricimab is primarily associated with ophthalmic applications and is administered by intravitreal injection. The marketed formulation is supplied as an aqueous solution containing 120 mg/mL, corresponding to a 6 mg/0.05 mL dose.
VEGF-A plays a major role in abnormal blood-vessel growth and increased vascular permeability in the retina. Ang-2 is another signaling molecule involved in vascular instability and inflammation.
Faricimab is designed to bind both VEGF-A and Ang-2, providing dual-pathway inhibition. This mechanism supports the control of abnormal retinal vascular leakage and angiogenic activity.
Faricimab is a biological pharmaceutical active ingredient rather than a conventional small-molecule API. Its quality assessment therefore relies on biological and protein-characterization techniques, including identity, purity, aggregation, charge variants, glycosylation, binding activity and biological potency.
Faricimab is used in ophthalmic medicine for the management of retinal vascular conditions. Its approved uses include:
Faricimab's dual targeting of VEGF-A and Ang-2 distinguishes it from therapies that primarily target the VEGF pathway alone.
As a recombinant monoclonal antibody, Faricimab requires specialized biological manufacturing and quality-control processes. Important quality attributes include protein identity, concentration, purity, aggregation, fragmentation, charge heterogeneity, glycosylation profile, binding activity and biological potency.
Manufacturing and release testing should be performed according to applicable GMP, pharmacopoeial and regulatory requirements, with product-specific acceptance criteria established through validated analytical methods.
Faricimab biological drug substance and finished product should be stored and handled according to the applicable manufacturer's validated stability and storage conditions. Temperature control and protection from unsuitable environmental conditions are important for maintaining protein stability.
| Parameter | Specification |
|---|---|
| Appearance | White to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.2% |
| Heavy Metals | NMT 20 ppm |
| pH (1% Solution) | 5.3 – 5.8 |
| Individual Impurity | ≤ 0.5% |
| Total Impurities | ≤ 1.5% |